<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="brief-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Bioorg Med Chem Lett</journal-id>
      <journal-title-group>
        <journal-title>Bioorganic &amp; Medicinal Chemistry Letters</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0960-894X</issn>
      <issn pub-type="epub">1464-3405</issn>
      <publisher>
        <publisher-name>Elsevier Science Ltd</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3268354</article-id>
      <article-id pub-id-type="pmid">22192589</article-id>
      <article-id pub-id-type="publisher-id">BMCL18373</article-id>
      <article-id pub-id-type="doi">10.1016/j.bmcl.2011.11.093</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pharmacophore-based discovery of a novel cytosolic phospholipase A<sub>2</sub>α inhibitor</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Noha</surname>
            <given-names>Stefan M.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jazzar</surname>
            <given-names>Bianca</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kuehnl</surname>
            <given-names>Susanne</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rollinger</surname>
            <given-names>Judith M.</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stuppner</surname>
            <given-names>Hermann</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schaible</surname>
            <given-names>Anja M.</given-names>
          </name>
          <xref rid="aff4" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Werz</surname>
            <given-names>Oliver</given-names>
          </name>
          <xref rid="aff4" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wolber</surname>
            <given-names>Gerhard</given-names>
          </name>
          <xref rid="aff5" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schuster</surname>
            <given-names>Daniela</given-names>
          </name>
          <email>Daniela.Schuster@uibk.ac.at</email>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="cor1" ref-type="corresp">⁎</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Institute of Pharmacy/Pharmaceutical Chemistry, Computer-Aided Molecular Design (CAMD) Group and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80/82, AT-6020 Innsbruck, Austria</aff>
      <aff id="aff2"><label>b</label>Department of Pharmaceutical Analytics, Pharmaceutical Institute, University of Tuebingen, Auf der Morgenstelle 8, DE-72076 Tuebingen, Germany</aff>
      <aff id="aff3"><label>c</label>Institute of Pharmacy/Pharmacognosy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80/82, AT-6020 Innsbruck, Austria</aff>
      <aff id="aff4"><label>d</label>Chair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University Jena, Philosophenweg 14, DE-07743 Jena, Germany</aff>
      <aff id="aff5"><label>e</label>Institute of Pharmacy/Pharmaceutical Chemistry, Königin-Luise-Str. 2+4, DE-14195 Berlin, Germany</aff>
      <author-notes>
        <corresp id="cor1"><label>⁎</label>Corresponding author. Tel.: +43 (0)512 507 58253; fax: +43 512 507 5269. <email>Daniela.Schuster@uibk.ac.at</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>15</day>
        <month>1</month>
        <year>2012</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2012</year>
      </pub-date>
      <volume>22</volume>
      <issue>2</issue>
      <fpage>1202</fpage>
      <lpage>1207</lpage>
      <history>
        <date date-type="received">
          <day>5</day>
          <month>10</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>18</day>
          <month>11</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>11</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2012 Elsevier Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="graphical">
        <title>Graphical abstract</title>
        <fig id="f0040" position="anchor">
          <graphic xlink:href="fx1"/>
        </fig>
      </abstract>
      <abstract>
        <p>The release of arachidonic acid, a precursor in the production of prostaglandins and leukotrienes, is achieved by activity of the cytosolic phospholipase A<sub>2</sub>α (cPLA<sub>2</sub>α). Signaling mediated by this class of bioactive lipids, which are collectively referred to as eicosanoids, has numerous effects in physiological and pathological processes. Herein, we report the development of a ligand-based pharmacophore model and pharmacophore-based virtual screening of the National Cancer Institute (NCI) database, leading to the identification of 4-(hexadecyloxy)-3-(2-(hydroxyimino)-3-oxobutanamido)benzoic acid (NSC 119957) as cPLA<sub>2</sub>α inhibitor in cell-free and cell-based in vitro assays.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Cytosolic phospholipase A<sub>2</sub>α</kwd>
        <kwd>cPLA<sub>2</sub>α</kwd>
        <kwd>Inflammation</kwd>
        <kwd>Pharmacophore modeling</kwd>
        <kwd>Virtual screening</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>During the last decade, efforts have been made to identify novel selective inhibitors of cytosolic phospholipase A<sub>2</sub>α (cPLA<sub>2</sub>α), which is a member of the PLA<sub>2</sub> family.<xref rid="b0005" ref-type="bibr"><sup>1</sup></xref> In general, the members of this superfamily have a crucial role in the production of prostaglandins (PGs) and leukotrienes (LTs). These lipolytic enzymes cleave arachidonic acid (AA) from the esters of membrane phospholipids in sn-2 position. The further production of PGs and LTs, collectively referred to as eicosanoids, is catalyzed by several downstream-functioning enzymes such as cyclooxygenases or 5-lipoxygenase.<xref rid="b0010 b0015 b0020" ref-type="bibr"><sup>2–4</sup></xref></p>
    <p>Several non-selective and selective inhibitors of cPLA<sub>2</sub>α have been reported (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). The published in vivo data of these inhibitors in models of inflammation confirms their efficacy.<xref rid="b0025 b0030 b0035 b0040 b0045 b0050 b0055" ref-type="bibr"><sup>5–11</sup></xref> Therefore, and based on data obtained from cPLA<sub>2</sub>α deficient mice, cPLA<sub>2</sub>α is considered an interesting target for the treatment of several inflammatory and allergic diseases.<xref rid="b0060 b0065" ref-type="bibr"><sup>12,13</sup></xref> Recently, the role of cPLA<sub>2</sub>α in prostate cancer was characterized.<xref rid="b0070" ref-type="bibr"><sup>14</sup></xref></p>
    <p>The active site of cPLA<sub>2</sub>α is arranged around a catalytic dyad, composed of Ser228 and Asp549. The translocation of cPLA<sub>2</sub>α to the perinuclear membrane is induced by an increase of the intracellular Ca<sup>2+</sup> concentration. The interaction of the enzyme with the lipid interface is assumed to induce a substantial change of the enzyme conformation including the movement of a loop that covers the active site, referred to as lid region. This profound change allows the lipid substrate to bind to the active site. Furthermore, phosphorylation of the enzyme at Ser505 by mitogen-activated protein kinases (MAPKs) alters the active site conformation.<xref rid="b0075" ref-type="bibr"><sup>15</sup></xref> In summary, large changes of the enzyme conformation result from interaction with the lipid interface and from phosphorylation by MAPKs. Therefore, the X-ray crystal structure of cPLA<sub>2</sub>α (PDB ID: <ext-link ext-link-type="uri" xlink:href="pdb:1cjy">1cjy</ext-link>), representing an inactive state of the hydrolase, was not used for structure-based modeling. Instead, virtual screening was conducted by using a ligand-based 3D pharmacophore model. In general, 3D pharmacophore modeling and pharmacophore-based screening have been established in drug discovery for several applications that include lead identification, lead optimization, and de novo design.<xref rid="b0080 b0085" ref-type="bibr"><sup>16,17</sup></xref> To our best knowledge, pharmacophore modeling of cPLA<sub>2</sub>α inhibitors has not been reported before. Herein, we report the development of a ligand-based pharmacophore model for cPLA<sub>2</sub>α inhibitors as well as pharmacophore-based virtual screening, in order to identify novel chemical classes of cPLA<sub>2</sub>α ligands.</p>
    <p>In order to develop ligand-based pharmacophore models, the 3D models were generated using the HipHop refine module in Catalyst 4.11 from Accelrys (<ext-link ext-link-type="uri" xlink:href="http://www.accelrys.com">http://www.accelrys.com</ext-link>).<xref rid="b0090" ref-type="bibr"><sup>18</sup></xref> The discriminatory power of the retrieved pharmacophore models was investigated by screening two datasets. The first one was a test set of highly active inhibitors that were not included in the training set. As putatively inactive molecules, so-called decoys, a compound collection assembled from the ChEMBL 03, from which reported inhibitors of all PLA<sub>2</sub> subtypes had previously been removed, was screened. The enrichment obtained in the screening experiments was quantitatively investigated by two enrichment metrics. The model with the highest enrichment of active compounds was selected for a virtual screening campaign of the National Cancer Institute (NCI) database. Afterward, compounds were submitted for evaluation in biological testings after visual inspection of the hit list (<xref rid="f0010" ref-type="fig">Fig. 2</xref>).</p>
    <p>Out of a heterogeneous dataset of cPLA<sub>2</sub>α inhibitors, examples shown in <xref rid="f0005" ref-type="fig">Figure 1</xref>, this molecular modeling study focused on three chemical classes that are composed of an aryl-alkyl-/alkyl-(oxy) side chain, a central carbonyl moiety, and in most cases of two to three aromatic rings.</p>
    <p>First, conformational models of the training set compounds (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) were generated with a maximum number of 255 conformations per molecule and ‘BEST’ quality within Catalyst. For the common feature pharmacophore hypotheses generation, the HipHop algorithm was used.<xref rid="b0095 b0100" ref-type="bibr"><sup>19,20</sup></xref> Using HipHop refine, these models were fine-tuned by strategically placing XVOLs in approximated forbidden areas from steric hindrance.<xref rid="b0105" ref-type="bibr"><sup>21</sup></xref> For this reason, the activity order of the training set compounds is a mandatory input for hypothesis generation. Highly active and medium active training set compounds are labeled with 2 and 1, respectively, and weakly or inactive compounds with 0.<xref rid="b0110" ref-type="bibr"><sup>22</sup></xref></p>
    <p>In brief, the hypothesis generation was performed by using six highly active (class 2) inhibitors from the diaryloxy-propan-2-one and the 5-carboxyindole-1-yl-propan-2-one scaffolds (<bold>6</bold>–<bold>11</bold>),<xref rid="b0115 b0120" ref-type="bibr"><sup>23,24</sup></xref> and four moderately active inhibitors (class 1), namely the 2-oxoamide inhibitor <bold>1</bold>,<xref rid="b0025" ref-type="bibr"><sup>5</sup></xref> and three diaryloxy-propan-2-one inhibitors (<bold>12</bold>–<bold>14</bold>)<xref rid="b0125 b0130" ref-type="bibr"><sup>25,26</sup></xref> (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A). The algorithm uses the information of medium active compounds to conduct a ranking of initially generated hypotheses. The hypotheses that map the highly active inhibitors and the moderately active inhibitors in consistency with their experimental data are prioritized. Additionally, four weakly active or inactive compounds (<bold>15</bold>–<bold>18</bold>), selected basically from the same chemical classes,<xref rid="b0125 b0130" ref-type="bibr"><sup>25,26</sup></xref> were used for the steric refinement step (<xref rid="f0015" ref-type="fig">Fig. 3</xref>B). A summary of the training set compounds with the assigned activity classes is given in <xref rid="t0005" ref-type="table">Table 1</xref>. The generation of 3D pharmacophore models resulted in ten hypotheses, of which seven models consisted of six features, two were composed of five features, and one of seven features, respectively.</p>
    <p>In order to perform the theoretical evaluation of the generated hypotheses, a set of 12 highly active compounds that were not included in the training set was assembled (<xref rid="f0020" ref-type="fig">Fig. 4</xref>). Furthermore, reported PLA<sub>2</sub> inhibitors were removed from the ChEMBL 03, a database of drugs and drug-like compounds with pharmacological activity notes.<xref rid="b0135" ref-type="bibr"><sup>27</sup></xref> Afterwards, this database that consisted of 310732 unique entries was refined by applying a physicochemical property-based filter. In total, 1712 compounds similar in physicochemical properties to the highly active compounds were selected using a protocol in PipelinePilot 7.5,<xref rid="b0140" ref-type="bibr"><sup>28</sup></xref> which is summarized in <xref rid="t0010" ref-type="table">Table 2</xref>. The conformational models for this validation dataset were generated within Catalyst 4.11 with a maximum number of 100 conformations per molecule and ‘FAST’ quality.</p>
    <p>The enrichment of active molecules was quantitatively investigated by the enrichment factor (EF) using the equation,<disp-formula id="e0005"><alternatives><textual-form specific-use="jats-markup">EF = [n / TP] / [A / N]</textual-form><mml:math id="M1" altimg="si1.gif" overflow="scroll"><mml:mtext>EF</mml:mtext><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mtext>n</mml:mtext><mml:mo>/</mml:mo><mml:mtext>TP</mml:mtext><mml:mo stretchy="false">]</mml:mo><mml:mo>/</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mtext>A</mml:mtext><mml:mo>/</mml:mo><mml:mtext>N</mml:mtext><mml:mo stretchy="false">]</mml:mo></mml:math></alternatives></disp-formula></p>
    <p>where TP is the number of active compounds correctly identified by screening with the 3D pharmacophore model (true positives), <italic>n</italic> is the total number of molecules retrieved by screening with the pharmacophore query (selection), <italic>A</italic> is the number of active compounds in the entire validation dataset (Actives), and <italic>N</italic> is the number of all compounds in the validation dataset (Number of entries in the validation dataset).<xref rid="b0170" ref-type="bibr"><sup>29</sup></xref></p>
    <p>Screening of this validation set with the 4th-ranked model (<xref rid="f0025" ref-type="fig">Fig. 5</xref>) retrieved 9 out of 12 active compounds (75.0%) and 14 out of 1712 inactive compounds (0.8%) using ‘fast flexible search’. Additionally, the Receiver Operating Characteristic (ROC) curve method was used for the quality control.<xref rid="b0150 b0155" ref-type="bibr"><sup>30,31</sup></xref> The area under the curve (AUC) of the displayed ROC plot can be used as measure for the enrichment of a screening method, referred to as ROC/AUC. This enrichment plot, a two-dimensional graph that displays the true positive rate (sensitivity) against the false positive rate (1-specificity), is used for the evaluation to address the issue of early enrichment in virtual screening experiments. In detail, this enrichment plot is described elsewhere.<xref rid="b0150 b0160" ref-type="bibr"><sup>30,32</sup></xref></p>
    <p>The EF of 56.2 and the ROC/AUC of 0.87 (<xref rid="f0030" ref-type="fig">Fig. 6</xref>) pointed towards an excellent model quality, and represented the best results of all created models.</p>
    <p>To experimentally evaluate the predictive power of the developed 3D pharmacophore model, the NCI database (247041 entries) was virtually screened.<xref rid="b0165" ref-type="bibr"><sup>33</sup></xref> For the generation of the conformational models for the NCI compounds a maximum number of 100 conformations per molecule and ‘FAST’ quality was employed. The virtual screening was performed using ‘fast flexible search’ and returned 185 hits (0.07%). For the selection of test compounds, we focused on (i) structurally diverse compounds, (ii) which were available at the time of our study, and (iii) which achieved high pharmacophore fit values. For assessment of cPLA<sub>2</sub>α inhibition, a cell-free in vitro assay based on isolated human recombinant cPLA<sub>2</sub>α was used and the cPLA<sub>2</sub>α reference inhibitor N-{(2S,4R)-4-(biphenyl-2-ylmethyl-isobutyl-amino)-1-[2-(2,4-difluorobenzoyl)-benzoyl]-pyrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenyl]acrylamide (compound <bold>43</bold>) was used as control to validate the assay (for details see <xref rid="s0010" ref-type="sec">Supplementary data</xref>). Biological evaluation of 12 virtual hits showed that compound <bold>31</bold> (<xref rid="f0035" ref-type="fig">Fig. 7</xref>) inhibited isolated human recombinant cPLA<sub>2</sub>α in the cell-free assay with an IC<sub>50</sub> value in the low micromolar range (IC<sub>50</sub> = 4 μM; <xref rid="s0010" ref-type="sec">Supplementary data Fig. S1</xref>). All other compounds (<bold>32</bold>–<bold>42</bold>, <xref rid="s0010" ref-type="sec">Supplementary data Chart S1</xref>) failed to inhibit cPLA<sub>2</sub>α activity at a concentration of 10 μM by more than 40%. Higher concentrations than 10 μM were not tested due to poor solubility in the aqueous assay buffer. The novel bioactive compound <bold>31</bold> was further analyzed for inhibition of cPLA<sub>2</sub>α-mediated AA release in a cell-based model using Ca<sup>2+</sup>-ionophore A23187-stimulated human monocytes (for details see <xref rid="s0010" ref-type="sec">Supplementary data</xref>). In fact, <bold>31</bold> inhibited AA release from human monocytes with similar potency (IC<sub>50</sub> = 5 μM; <xref rid="s0010" ref-type="sec">Supplementary data</xref> Fig. S1) as in the cell-free in vitro assay. Again, the cPLA<sub>2</sub>α reference inhibitor <bold>43</bold> inhibited AA release as expected (<xref rid="s0010" ref-type="sec">Supplementary data Fig. S1</xref>). Together<bold><sub>,</sub></bold> compound <bold>31</bold> can be considered as an interesting candidate for further chemical optimization to obtain potent inhibitors of eicosanoid-related inflammation and cancer.</p>
    <p>The next step in the development represents the characterization of the pharmacological profile of <bold>31</bold> against other targets relevant in the production of PGs and LTs. Unfortunately, the identification of a novel chemical class not composed of a reactive moiety, such as an activated carbonyl group, was not achieved. The results even suggest that a reactive moiety is essential for the potency of the compounds investigated. This finding can be considered in the virtual screening workflow by including a pre-filtering step to recognize reactive moieties and a refinement of the 3D model.</p>
  </body>
  <back>
    <ref-list>
      <title>References and Notes</title>
      <ref id="b0005">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Magrioti</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kokotos</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <source>Expert Opin. Ther. Pat.</source>
          <volume>20</volume>
          <year>2010</year>
          <fpage>1</fpage>
          <pub-id pub-id-type="pmid">20021282</pub-id>
        </element-citation>
      </ref>
      <ref id="b0010">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niknami</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Witting</surname>
              <given-names>P.K.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Q.</given-names>
            </name>
          </person-group>
          <source>Int. J. Biochem. Cell Biol.</source>
          <volume>41</volume>
          <year>2009</year>
          <fpage>994</fpage>
          <pub-id pub-id-type="pmid">18761105</pub-id>
        </element-citation>
      </ref>
      <ref id="b0015">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimizu</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ohto</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kita</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <source>IUBMB Life</source>
          <volume>58</volume>
          <year>2006</year>
          <fpage>328</fpage>
          <pub-id pub-id-type="pmid">16754327</pub-id>
        </element-citation>
      </ref>
      <ref id="b0020">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burke</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Dennis</surname>
              <given-names>E.A.</given-names>
            </name>
          </person-group>
          <source>J. Lipid Res.</source>
          <year>2009</year>
          <fpage>S237</fpage>
          <pub-id pub-id-type="pmid">19011112</pub-id>
        </element-citation>
      </ref>
      <ref id="b0025">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kokotos</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Six</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Loukas</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Constantinou-Kokotou</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Hadjipavlou-Litina</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kotsovolou</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chiou</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Beltzner</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Dennis</surname>
              <given-names>E.A.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>47</volume>
          <year>2004</year>
          <fpage>3615</fpage>
          <pub-id pub-id-type="pmid">15214789</pub-id>
        </element-citation>
      </ref>
      <ref id="b0030">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tai</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Kuwabara</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Seno</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Gahara</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ishizaki</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hori</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <source>Inflamm. Res.</source>
          <volume>59</volume>
          <year>2010</year>
          <fpage>53</fpage>
          <pub-id pub-id-type="pmid">19655230</pub-id>
        </element-citation>
      </ref>
      <ref id="b0035">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Behnke</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Vargas</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Nunez</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tam</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mollova</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Ramarao</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Goodwin</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Nickerson-Nutter</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>W.M.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>McKew</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <source>Bioorg. Med. Chem.</source>
          <volume>16</volume>
          <year>2008</year>
          <fpage>1345</fpage>
          <pub-id pub-id-type="pmid">17998165</pub-id>
        </element-citation>
      </ref>
      <ref id="b0040">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKew</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Thakker</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Behnke</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Sum</surname>
              <given-names>F.W.</given-names>
            </name>
            <name>
              <surname>Tam</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Kirincich</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Michalak</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Thomason</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ipek</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wooder</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Ramarao</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Goodwin</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Albert</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Donahue</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Ku</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Keith</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Nickerson-Nutter</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>W.M.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hegen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>J.D.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>51</volume>
          <year>2008</year>
          <fpage>3388</fpage>
          <pub-id pub-id-type="pmid">18498150</pub-id>
        </element-citation>
      </ref>
      <ref id="b0045">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drews</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bovens</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Roebrock</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Sunderkotter</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Reinhardt</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Schafers</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>van der Velde</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schulze Elfringhoff</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Fabian</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lehr</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>53</volume>
          <year>2010</year>
          <fpage>5165</fpage>
          <pub-id pub-id-type="pmid">20583844</pub-id>
        </element-citation>
      </ref>
      <ref id="b0050">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagase</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Uozumi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Aoki-Nagase</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Terawaki</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hashizume</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ouchi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <source>Am. J. Physiol. Lung Cell. Mol. Physiol.</source>
          <volume>284</volume>
          <year>2003</year>
          <fpage>L720</fpage>
          <pub-id pub-id-type="pmid">12505870</pub-id>
        </element-citation>
      </ref>
      <ref id="b0055">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Behnke</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Lovering</surname>
              <given-names>F.E.</given-names>
            </name>
            <name>
              <surname>Kirincich</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Shim</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tam</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Khor</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Goodwin</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Ramarao</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Nickerson-Nutter</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Donahue</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Ku</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>McKew</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>50</volume>
          <year>2007</year>
          <fpage>1380</fpage>
          <pub-id pub-id-type="pmid">17305324</pub-id>
        </element-citation>
      </ref>
      <ref id="b0060">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uozumi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Kume</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Nagase</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nakatani</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tashiro</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Komagata</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Maki</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ikuta</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ouchi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Miyazaki</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <source>Nature</source>
          <volume>390</volume>
          <year>1997</year>
          <fpage>618</fpage>
          <pub-id pub-id-type="pmid">9403692</pub-id>
        </element-citation>
      </ref>
      <ref id="b0065">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whalen</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Legault</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kasaian</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Donaldson</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bensch</surname>
              <given-names>G.W.</given-names>
            </name>
            <name>
              <surname>Bensch</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Ramarao</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>D.K.</given-names>
            </name>
            <name>
              <surname>Csimma</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>McKee</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Dorner</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>O’Toole</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <source>Clin. Exp. Allergy</source>
          <volume>38</volume>
          <year>2008</year>
          <fpage>1590</fpage>
          <pub-id pub-id-type="pmid">18665843</pub-id>
        </element-citation>
      </ref>
      <ref id="b0070">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patel</surname>
              <given-names>M.I.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Niknami</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kurek</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Maclean</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>Gelb</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>K.F.</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Boulas</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Q.</given-names>
            </name>
          </person-group>
          <source>Clin. Cancer Res.</source>
          <volume>14</volume>
          <year>2008</year>
          <fpage>8070</fpage>
          <pub-id pub-id-type="pmid">19088022</pub-id>
        </element-citation>
      </ref>
      <ref id="b0075">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haeggstrom</surname>
              <given-names>J.Z.</given-names>
            </name>
            <name>
              <surname>Rinaldo-Matthis</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wheelock</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Wetterholm</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>396</volume>
          <year>2010</year>
          <fpage>135</fpage>
          <pub-id pub-id-type="pmid">20494126</pub-id>
        </element-citation>
      </ref>
      <ref id="b0080">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langer</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <source>Mol. Inf.</source>
          <volume>29</volume>
          <year>2010</year>
          <fpage>470</fpage>
        </element-citation>
      </ref>
      <ref id="b0085">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>S.Y.</given-names>
            </name>
          </person-group>
          <source>Drug Discov. Today</source>
          <volume>15</volume>
          <year>2010</year>
          <fpage>444</fpage>
          <pub-id pub-id-type="pmid">20362693</pub-id>
        </element-citation>
      </ref>
      <ref id="b0090">
        <label>18</label>
        <mixed-citation publication-type="other">Accelrys Software Inc.: San Diego, CA, 2005.</mixed-citation>
      </ref>
      <ref id="b0095">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurogi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Güner</surname>
              <given-names>O.F.</given-names>
            </name>
          </person-group>
          <source>Curr. Med. Chem.</source>
          <volume>8</volume>
          <year>2001</year>
          <fpage>1035</fpage>
          <pub-id pub-id-type="pmid">11472240</pub-id>
        </element-citation>
      </ref>
      <ref id="b0100">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leach</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Gillet</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>53</volume>
          <year>2010</year>
          <fpage>539</fpage>
          <pub-id pub-id-type="pmid">19831387</pub-id>
        </element-citation>
      </ref>
      <ref id="b0105">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noha</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Atanasov</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Schuster</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Markt</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Fakhrudin</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Heiss</surname>
              <given-names>E.H.</given-names>
            </name>
            <name>
              <surname>Schrammel</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Rollinger</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Stuppner</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Dirsch</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Wolber</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <source>Bioorg. Med. Chem. Lett.</source>
          <volume>21</volume>
          <year>2011</year>
          <fpage>577</fpage>
          <pub-id pub-id-type="pmid">21078555</pub-id>
        </element-citation>
      </ref>
      <ref id="b0110">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schuster</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Spetea</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Music</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rief</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fink</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kirchmair</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Schutz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wolber</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Langer</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Stuppner</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Schmidhammer</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Rollinger</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <source>Bioorg. Med. Chem.</source>
          <volume>18</volume>
          <year>2010</year>
          <fpage>5071</fpage>
          <pub-id pub-id-type="pmid">20580236</pub-id>
        </element-citation>
      </ref>
      <ref id="b0115">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ludwig</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bovens</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Brauch</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Elfringhoff</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Lehr</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>49</volume>
          <year>2006</year>
          <fpage>2611</fpage>
          <pub-id pub-id-type="pmid">16610804</pub-id>
        </element-citation>
      </ref>
      <ref id="b0120">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Connolly</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bennion</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Botterell</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Croshaw</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Hallam</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hartopp</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>C.G.</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Mete</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Walters</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Withnall</surname>
              <given-names>W.J.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>45</volume>
          <year>2002</year>
          <fpage>1348</fpage>
          <pub-id pub-id-type="pmid">11882004</pub-id>
        </element-citation>
      </ref>
      <ref id="b0125">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fritsche</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Elfringhoff</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Fabian</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lehr</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <source>Bioorg. Med. Chem.</source>
          <volume>16</volume>
          <year>2008</year>
          <fpage>3489</fpage>
          <pub-id pub-id-type="pmid">18321717</pub-id>
        </element-citation>
      </ref>
      <ref id="b0130">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walters</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Bennion</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Connolly</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Croshaw</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hartopp</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>C.G.</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Mete</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>John Withnall</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <source>Bioorg. Med. Chem. Lett.</source>
          <volume>14</volume>
          <year>2004</year>
          <fpage>3645</fpage>
          <pub-id pub-id-type="pmid">15203135</pub-id>
        </element-citation>
      </ref>
      <ref id="b0135">
        <label>27</label>
        <mixed-citation publication-type="other">ChEMBL version 03, http://www.ebi.ac.uk/chembldb/.</mixed-citation>
      </ref>
      <ref id="b0140">
        <label>28</label>
        <mixed-citation publication-type="other">SciTegic: San Diego, CA, 2008.</mixed-citation>
      </ref>
      <ref id="b0170">
        <label>29</label>
        <element-citation publication-type="book">
          <person-group person-group-type="editor">
            <name>
              <surname>Güner</surname>
              <given-names>O.F.</given-names>
            </name>
            <name>
              <surname>Waldman</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J.H.</given-names>
            </name>
          </person-group>
          <source>Strategies for database mining and pharmacophore development</source>
          <year>2000</year>
          <publisher-name>International University Line</publisher-name>
          <publisher-loc>La Jolla, CA, U.S.A.</publisher-loc>
        </element-citation>
      </ref>
      <ref id="b0150">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Triballeau</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Acher</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Brabet</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Pin</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Bertrand</surname>
              <given-names>H.O.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>48</volume>
          <year>2005</year>
          <fpage>2534</fpage>
          <pub-id pub-id-type="pmid">15801843</pub-id>
        </element-citation>
      </ref>
      <ref id="b0155">
        <label>31</label>
        <mixed-citation publication-type="other">The statistical evaluation was performed using Analyse-it for Microsoft Excel (version 2.20). Analyse-it Software, Ltd. http://www.analyse-it.com/ 2009.</mixed-citation>
      </ref>
      <ref id="b0160">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clark</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Webster-Clark</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <source>J. Comput. Aided Mol. Des.</source>
          <volume>22</volume>
          <year>2008</year>
          <fpage>141</fpage>
          <pub-id pub-id-type="pmid">18256892</pub-id>
        </element-citation>
      </ref>
      <ref id="b0165">
        <label>33</label>
        <mixed-citation publication-type="other">National Cancer Institute, Release 2003. http://dtp.nci.nih.gov//docs/dtp_search.html.</mixed-citation>
      </ref>
    </ref-list>
    <sec id="s0010" sec-type="supplementary-material">
      <title>Supplementary data</title>
      <p>
        <supplementary-material content-type="local-data" id="m0005">
          <caption>
            <title>Supplementary data</title>
            <p>General procedures.</p>
          </caption>
          <media xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/>
        </supplementary-material>
      </p>
    </sec>
    <ack>
      <title>Acknowledgments</title>
      <p>This work was funded by the NFN-Project ‘Drugs from nature targeting inflammation – DNTI’, from the Austrian Science Foundation (FWF Projects S10702/S10711 and S10703). We also thank Patrick Markt for his assistance in the theoretical model validation. S.M.N. is grateful for a Young Talents Grant from the University of Innsbruck. S.K. was supported by the Tyrolean Science Foundation (TWF). We acknowledge the NCI for providing the test compounds.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="f0005">
      <label>Figure 1</label>
      <caption>
        <p>Reported cPLA<sub>2</sub>α inhibitors with published in vivo data (for details see Ref.<xref rid="b0025 b0030 b0035 b0040 b0045 b0050 b0055" ref-type="bibr"><sup>5–11</sup></xref>).</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="f0010">
      <label>Figure 2</label>
      <caption>
        <p>Workflow for the development of the cPLA<sub>2</sub>α inhibitor pharmacophore model.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="f0015">
      <label>Figure 3</label>
      <caption>
        <p>Highly active and active training set compounds for the HipHop refine model (A) and weakly or inactive compounds for the steric refinement (B).</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="f0020">
      <label>Figure 4</label>
      <caption>
        <p>Test set for the theoretical model validation.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="f0025">
      <label>Figure 5</label>
      <caption>
        <p>Representation of the 3D pharmacophore model—Chemical features are color coded: cyan - hydrophobic feature, green - hydrogen-bond acceptor, and blue - negative ionizable (A). Mapping of the biologically active virtual hit compound <bold>31</bold> to the model (B).</p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
    <fig id="f0030">
      <label>Figure 6</label>
      <caption>
        <p>ROC curve for the theoretical validation of the developed 3D pharmacophore model.</p>
      </caption>
      <graphic xlink:href="gr6"/>
    </fig>
    <fig id="f0035">
      <label>Figure 7</label>
      <caption>
        <p>Biologically active compound <bold>31</bold>.</p>
      </caption>
      <graphic xlink:href="gr7"/>
    </fig>
    <table-wrap id="t0005" position="float">
      <label>Table 1</label>
      <caption>
        <p>Training set compounds for the HipHop refine model</p>
      </caption>
    </table-wrap>
    <table-wrap id="t0010" position="float">
      <label>Table 2</label>
      <caption>
        <p>Physicochemical property analysis of the dataset of cPLA<sub>2</sub>α inhibitors and the putatively inactive ChEMBL compounds (‘decoys’)</p>
      </caption>
    </table-wrap>
  </floats-group>
</article>